NIKKEI 225
40,074.69 +443.63 (+1.12%) HANG SENG
17,769.14 +50.53 (+0.29%) CRUDE OIL
83.43 +0.05 (+0.06%) GOLD FUTURES
2,330.20 -8.70 (-0.37%) DOW
39,124.07 -45.45 (-0.12%) Bitcoin GBP
48,761.62 -1,049.59 (-2.11%)
AVXL Jan 2026 20.000 call
- Simply Wall St.
Institutions own 38% of Anavex Life Sciences Corp. (NASDAQ:AVXL) shares but individual investors control 59% of the company
Key Insights Significant control over Anavex Life Sciences by individual investors implies that the general public has...
- GlobeNewswire
Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsychiatric disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today announced that Christopher U. Missling, PhD, President and Chief Executive O
- GlobeNewswire
Anavex Life Sciences Announces Expansion of Leadership Team
Strengthening Operational Efficiency and Execution towards Sustainable Accessibility for Diverse Populations within Global Healthcare SystemsNEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schiz
